CD274 and neoplasm: With the breakthrough progress of PD-1 inhibitor and PD-L1 inhibitor in the immunotherapy of melanoma, non-small cell lung cancer, kidney cancer and other tumours, the research on EC was gradually launched, and initial results were achieved (11).